

BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107 Asset Class: Stock

| | |
|-------------------|-----------------------|
| Company | 2024/05/03 22:00:01 |
| Price | 7.82 USD |
| Difference | -3.34% (-0.27) |



Contact Details

| | |
|--------------------------------|----------------------------------------------------------------------------|
| BAUSCH HEALTH COS. INC. | Tel: +1-514-744-6792 |
| -- | Fax: + |
| 2150 St. Elzéar Boulevard West | Web: http://www.bauschhealth.com |
| H7L 4A8 Laval | E-mail: - |

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 7,378,885,000 | | 5,754,472,000 | | 7,082,482,000 | |
| Common stock capital | | 13,743,767,000 | | 14,079,285,000 | | 13,031,918,000 |
| Fixed assets | 28,684,824,000 | | 29,048,773,000 | | 29,804,024,000 | |
| Equity capital of a company | | -108,125,000 | | 352,287,000 | | -42,947,000 |
| Cash and cash equivalents | 1,268,493,000 | | 800,775,000 | | 2,676,614,000 | |
| Accrued liabilities | | 0 | | 0 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 5,672,617,000 | | 5,339,857,000 | | 6,565,853,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 30,499,218,000 | | 29,111,100,000 | | 30,363,599,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 1,161,686,000 | | 1,036,536,000 | | 809,679,000 |
| Total assets | 36,063,710,000 | 36,063,710,000 | 34,803,245,000 | 34,803,245,000 | 36,886,506,000 | 36,886,506,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|-----------|-----------|------------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 20,270 | 19,900 | 19,100 |
| Equity ratio | 3.14% | 4.72% | 0.13% |
| Debt-equity ratio | 3,087.65% | 2,019.31% | 76,747.37% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|---------|---------|-------|
| Tax Expense Rate | -56.67% | -64.34% | 8.50% |

BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107 Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|----------------------------------------------------------------------|----------------|----------------|----------------|
| Turnover | 11,819,208,000 | 10,576,257,000 | 10,573,980,000 |
| Net income | -799,014,000 | -292,917,000 | -1,188,538,000 |
| EBIT | 902,052,081 | 1,227,675,569 | 387,847,829 |
| Operating income before taxes | -526,377,000 | -167,939,000 | -1,283,822,000 |
| Cash Flow | 1,344,288,000 | -1,040,180,000 | 1,727,643,000 |
| Net interest income | -1,853,120,000 | -1,973,609,000 | -1,854,270,000 |
| Research and development expenses | 815,210,000 | 688,680,000 | 582,985,000 |
| Income taxes | 298,280,000 | 108,053,000 | -109,074,000 |
| Result from investments in subsidiaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 396,442 | 361,347 | 376,401 |

Board of Directors

| | |
|------------------|-------------------------------|
| John Paulson | Chairman of Supervisory Board |
| Amy Wechsler | Member of Supervisory Board |
| Richard Mulligan | Member of Supervisory Board |
| Brett Icahn | Member of Supervisory Board |
| Robert Power | Member of Supervisory Board |
| Russel Robertson | Member of Supervisory Board |
| Sarah Kavanagh | Member of Supervisory Board |
| Steven Miller | Member of Supervisory Board |
| Thomas Ross | Member of Supervisory Board |

Members of Management Board

| | |
|----------------------|-------------------------------|
| Thomas Appio | Chairman of Managing Board |
| Tage Ramakrishna | Member of Executive Committee |
| Cees Heiman | Member of Executive Committee |
| Fernando Zarate | Member of Executive Committee |
| Graham Jackson | Member of Executive Committee |
| Jeff Hartness | Member of Executive Committee |
| Kathleen Fitzpatrick | Member of Executive Committee |
| Mirza Dautbegovic | Member of Executive Committee |
| Seana Carson | Member of Executive Committee |
| Tom Vadaketh | Member of Executive Committee |